Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 909

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 909
---
   |            |   |        |   | ​ |
|:-----------------------------|:--|:--|:------------------------|:--|-------:|:--|:--|:--|:----------------|:--|--:|:--|:--|:--|:-----------------|:--|----:|:--|:--|:--|:-----------|:--|-------:|:--|:--|
| ​                            | ​ | ​ | AmortizedCost           |   |        |   | ​ | ​ | UnrealizedGains |   |   |   | ​ | ​ | UnrealizedLosses |   |     |   | ​ | ​ | Fair Value |   |        |   | ​ |
| Short-term investments       | ​ | ​ | ​                       | ​ |      ​ | ​ | ​ | ​ | ​               | ​ | ​ | ​ | ​ | ​ | ​                | ​ |   ​ | ​ | ​ | ​ | ​          | ​ |      ​ | ​ | ​ |
| U.S. Treasury Notes          | ​ | ​ | ​                       | $ | 22,274 | ​ | ​ | ​ | ​               | $ | 8 | ​ | ​ | ​ | ​                | $ | -32 | ​ | ​ | ​ | ​          | $ | 22,250 | ​ | ​ |
| Total short-term investments | ​ | ​ | ​                       | $ | 22,274 | ​ | ​ | ​ | ​               | $ | 8 | ​ | ​ | ​ | ​                | $ | -32 | ​ | ​ | ​ | ​          | $ | 22,250 | ​ | ​ |

The Company had net unrealized losses of approximately $24,000 during the year ended December 31, 2022. Upon maturity of all of the Company’s short-term investments during the year ended December 31, 2023, the Company reversed this loss. The Company did not have short-term investments during the year ended December 31, 2023. The contractual maturities of the Company’s short-term investments in available-for-sale securities held were as follows (in thousands):

| ​                   | ​ | ​ | December 31,2022 |   |        |   | ​ |
|:--------------------|:--|:--|:-----------------|:--|-------:|:--|:--|
| Due within one year